(NASDAQ: EXAI) Exscientia's forecast annual revenue growth rate of 154.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 245.77%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.38%.
Exscientia's revenue in 2024 is $25,742,307.On average, 1 Wall Street analysts forecast EXAI's revenue for 2024 to be $8,236,020,986, with the lowest EXAI revenue forecast at $8,236,020,986, and the highest EXAI revenue forecast at $8,236,020,986.
In 2025, EXAI is forecast to generate $11,684,037,708 in revenue, with the lowest revenue forecast at $11,684,037,708 and the highest revenue forecast at $11,684,037,708.